PharmaCyte Biotech Accounts Payable

PharmaCyte Biotech (PMCB) currently reports a accounts payable of $1.2M as of January 2026. That compares with $480K in the prior-year period — up 147.5% year over year. Use the charts on this page to explore PharmaCyte Biotech's accounts payable history and peer comparisons.

PharmaCyte Biotech's accounts payable increased from $480K to $1.2M — a 147.5% year-over-year increase (period ending January 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

PharmaCyte Biotech reported $1.2M in accounts payable as of January 2026. That compares with $480K in the prior-year period — up 147.5% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current accounts payable of $1.2M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for PharmaCyte Biotech, and consider following PMCB for alerts when major investors trade the stock.

PharmaCyte Biotech is classified in the Healthcare sector. On accounts payable, it currently shows $1.2M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing PMCB with unrelated industries.